Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed.
NANTES, France (BUSINESS WIRE) Regulatory News:OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the presentation of two new analyses from the Phase 3 Atalante-1 study of immunotherapy Tedopi®, in patients with advanced non-small cell lung cancer (NSCLC) in secondary resistance after failure of.